Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peking University
Age
18–65
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Breast cancer patients in need for adjuvant chemotherapy confirmed by histopathology, whom should accept ddEC regimen.
ECOG\<=1
Expected survival is greater than 6 months
Qualified for chemotherapy，WBC\>=3\*109/L, ANC\>=1.5\*109/L, Hb\>=80g/L, PLT\>=80\*109/L. With no bleeding tendency or systemic hematology disorder symptoms.
No obvious EKG abnormality, no obvious cardiac dysfunction, and normal left ventricular ejection fraction.
Liver function, ALT and AST should less than 2.5 times of the upper limit.
Renal function, Cr and BUN should less than 1.5 times of the upper limit.
Subjects voluntarily participate in this study and sign informed consent.
You may not be if
Total amount of doxorubicin used in previous chemotherapy\>240mg/m2, or epirubicin\>360mg/m2
Has received hematopoietic stem cell transplantation or bone marrow transplantation
Other drugs are currently in clinical trials
There are currently hard-to-control infections, body temperature is higher than 38 degrees.
Received PEG-rhG-CSF treatment before enrollment
Received chemotherapy in 4 weeks before enrollment
Patients with any visceral metastasis
Patients with severe heart, kidney, liver or any other important organs chronic diseases
Patients with severe uncontrolled diabetes
Patients with allergic diseases, or allergies to this product or other biological products derived from genetically engineered e. coli
Suspected or real drug users, substance abusers, alcoholics
Pregnant or lactating women
Severe mental or neurological disorders that affect informed consent and adverse reactions described or observed
